Search
Maze Therapeutics Inc
MAZEAdd to Watchlist
31.290USD
+0.280+0.90%
Market hours 10/26, 11:19（ET）
1.69BMarket Cap
LossP/E TTM
Maze Therapeutics Inc (MAZE) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Maze Therapeutics Inc in the past month.
Buy
6 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
62.273USD+126.20%
MAZE Analyst Recommendation Trends
In the current month, MAZE has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MAZE average Analyst price target in the last month is 62.273.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
6
6
5
5
5
5
5
5
8
7
7
7
7
7
7
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
13
12
12
12
12
12
10
MAZE Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Biontech SE
BNTX
4
12
8
0
0
24
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, MAZE EPS is projected to reach -0.778 in FY2026Q3, following reported EPS of -0.758 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.71
-0.55
-0.73
-0.78
-0.82
Actual
-0.65
-0.45
-0.76
--
--
Surprise
+9.48%
+17.67%
-3.29%
--
--
FAQs
What is Maze Therapeutics Inc's price target?
Analysts forecast that Maze Therapeutics Inc's price target is USD 63.33, with the highest forecast at USD 110.00 and the lowest forecast at USD 46.00.
How have Maze Therapeutics IncMAZE's recent earnings per share performed?
The market expectation was USD -0.76, while Maze Therapeutics IncMAZE's earnings per share (EPS) for the previous quarter was USD -0.45. EPS for the next quarter is expected at USD -0.78.
What is the analyst rating for Maze Therapeutics Inc?
Based on the ratings of Maze Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.